Evidence map›Paper›PMID 41889934›Full record

ArticlebioRxiv : the preprint server for biology2026

Library docking for Cannabinoid-2 Receptor ligands.

Moira M Rachman, Christos Iliopoulos-Tsoutsouvas, Michael D Sacco, Xinyu Xu, Cheng-Guo Wu, Emma Santos, Isabella S Glenn, Lu Paris, Michelle K Cahill, Suthakar Ganapathy and 9 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Moira M RachmanDepartment of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th St., Byers Hall Rm 508D, San Francisco, CA 94143.ORCID 0000-0003-3671-8885
Christos Iliopoulos-TsoutsouvasCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA.
Michael D SaccoDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Xinyu XuDepartment of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th St., Byers Hall Rm 508D, San Francisco, CA 94143.
Cheng-Guo WuDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Emma SantosDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Isabella S GlennDepartment of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th St., Byers Hall Rm 508D, San Francisco, CA 94143.ORCID 0009-0002-6443-1873
Lu ParisDepartment of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th St., Byers Hall Rm 508D, San Francisco, CA 94143.
Michelle K CahillDepartment of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford CA 94305 USA.ORCID 0009-0008-7810-800X
Suthakar GanapathyCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA.
Tia A TumminoDepartment of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th St., Byers Hall Rm 508D, San Francisco, CA 94143.ORCID 0000-0001-9155-820X
Yurii S MorozEnamine Ltd., 67 Winston Churchill Street, Kyiv 02094, Ukraine.ORCID 0000-0001-6073-002X
Dmytro S RadchenkoEnamine Ltd., 67 Winston Churchill Street, Kyiv 02094, Ukraine.ORCID 0000-0001-5444-7754
Meri OkorieDepartment of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th St., Byers Hall Rm 508D, San Francisco, CA 94143.ORCID 0000-0002-0487-3031
Vivianne TawfikDepartment of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford CA 94305 USA.ORCID 0000-0002-4422-2014
John J IrwinDepartment of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th St., Byers Hall Rm 508D, San Francisco, CA 94143.
Alexandros MakriyannisCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA.
Georgios SkiniotisDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Brian K ShoichetDepartment of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th St., Byers Hall Rm 508D, San Francisco, CA 94143.

Funding

Development and Testing of New Computational Methods for Ligand Discovery and MechanismR35GM122481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian K Shoichet · 2017 to 2026
$8.5M
NIGMS NIH HHS R35 GM122481
6 · The paper itself

Abstract

Cannabinoid receptors are therapeutically promising GPCRs that are also interesting test systems for structure-based methods, which have targeted them previously. Here we used the CB2 receptor as a template to explore several topical questions in library docking. Whereas an earlier campaign against the CB1 receptor led to potent but relatively non-selective ligands, here we found that targeting interactions with polar, orthosteric site residues led to subtype-selective ligands. Docking hit rate and especially hit affinity improved in moving from a 7 million to a 2.6 billion molecule library. Similar to earlier studies, docking against active and inactive states of the receptor did not reliably bias toward the discovery of agonists or inverse agonists. Cryo-EM structures of two of the new agonists, each in a different chemotype, superposed well on the docking predictions. Correspondingly, structure-based optimization led to 10- to 140-fold improvements within three different series, also consistent with well-behaved ligand families. Hit rates with a fully enumerated 2.6 billion molecule library resembled those of an implied 11 billion molecule library from a building-block method, consistent with the latter's ability to explore this space, though higher affinities were discovered from the fully enumerated set. Overall, eight diverse families of ligands, with potencies <100 nM and mostly unrelated to previously known ligands were found. Implications for future studies are considered.

Identifiers

PMID41889934
PMCPMC13015411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.